Optiray (Ioversol)

Ioversol, the active ingredient in Optiray, is a non‑ionic iodinated contrast media presented as a sterile solution for intra‑arterial and intravenous use. It provides radiographic contrast enhancement for imaging procedures.

GNH USA supplies Optiray as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Optiray (Ioversol) is used as a radiographic contrast agent to enhance imaging of vascular and organ structures.

Angiography: improves visualization of blood vessels during angiographic procedures. Computed Tomography (CT) imaging: enhances contrast of tissues and vessels for clearer CT scans. Other radiographic procedures: provides contrast enhancement for various X‑ray based diagnostic studies.

Common Side Effects: - Warm sensation at injection site - Nausea - Metallic taste

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Contrast‑induced nephropathy - Thyroid dysfunction

Before using Optiray, consider the following precautions: - Assess renal function: evaluate serum creatinine and eGFR prior to administration. - Check for iodine allergy: avoid in patients with known hypersensitivity to iodinated contrast. - Hydration: ensure adequate fluid intake to reduce risk of nephrotoxicity. - Concurrent nephrotoxic drugs: use with caution or discontinue if possible. - Pregnancy and breastfeeding: use only if clearly needed after risk‑benefit assessment. - Store at ambient temperature: keep in original container, protect from light and moisture.

Optiray may interact with other medications as follows:

Major Interactions (Avoid): - Concurrent use of other iodinated contrast agents: may increase toxicity risk. - High‑dose nephrotoxic antibiotics (e.g., aminoglycosides): can exacerbate renal injury.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance; monitor kidney function. - Metformin: risk of lactic acidosis in renal impairment; consider temporary discontinuation. - ACE inhibitors or ARBs: may affect renal perfusion; monitor renal parameters.